These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9201249)
1. Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. Aviram A; Rephaeli A; Shaklai M; Nudelman A; Ben-Dror I; Maron L; Rabizadeh E J Cancer Res Clin Oncol; 1997; 123(5):267-71. PubMed ID: 9201249 [TBL] [Abstract][Full Text] [Related]
2. Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Rabizadeh E; Shaklai M; Eisenbach L; Nudelman A; Rephaeli A Isr J Med Sci; 1996 Dec; 32(12):1186-91. PubMed ID: 9007151 [TBL] [Abstract][Full Text] [Related]
3. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. Rabizadeh E; Shaklai M; Nudelman A; Eisenbach L; Rephaeli A FEBS Lett; 1993 Aug; 328(3):225-9. PubMed ID: 8348968 [TBL] [Abstract][Full Text] [Related]
4. Sodium butyrate inhibits c-myc and stimulates c-fos expression in all the steps of the cell-cycle in hepatoma tissue cultured cells. Tichonicky L; Kruh J; Defer N Biol Cell; 1990; 69(1):65-7. PubMed ID: 2261575 [TBL] [Abstract][Full Text] [Related]
5. Effects of sodium butyrate on the rearranged c-myc expression in mouse plasmacytoma cells. Kondoh N; Oikawa T; Satoh C; Kuzumaki N Exp Cell Res; 1991 Sep; 196(1):146-9. PubMed ID: 1879469 [TBL] [Abstract][Full Text] [Related]
6. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Knapp DC; Mata JE; Reddy MT; Devi GR; Iversen PL Anticancer Drugs; 2003 Jan; 14(1):39-47. PubMed ID: 12544257 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of 17 structural analogues of n-butyric acid upon c-myc expression. Rottleb C; Hall C; Bornkamm GW; Polack A Int J Cancer; 1996 Sep; 67(5):724-9. PubMed ID: 8782665 [TBL] [Abstract][Full Text] [Related]
8. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Coradini D; Pellizzaro C; Abolafio G; Bosco M; Scarlata I; Cantoni S; Stucchi L; Zorzet S; Turrin C; Sava G; Perbellini A; Daidone MG Invest New Drugs; 2004 Aug; 22(3):207-17. PubMed ID: 15122068 [TBL] [Abstract][Full Text] [Related]
9. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Rephaeli A; Entin-Meer M; Angel D; Tarasenko N; Gruss-Fischer T; Bruachman I; Phillips DR; Cutts SM; Haas-Kogan D; Nudelman A Invest New Drugs; 2006 Sep; 24(5):383-92. PubMed ID: 16502348 [TBL] [Abstract][Full Text] [Related]
10. Novel anticancer prodrugs of butyric acid. 2. Nudelman A; Ruse M; Aviram A; Rabizadeh E; Shaklai M; Zimrah Y; Rephaeli A J Med Chem; 1992 Feb; 35(4):687-94. PubMed ID: 1542095 [TBL] [Abstract][Full Text] [Related]
11. Regulation of c-myc expression by sodium butyrate in the colon carcinoma cell line Caco-2. Souleimani A; Asselin C FEBS Lett; 1993 Jul; 326(1-3):45-50. PubMed ID: 8325387 [TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227 [TBL] [Abstract][Full Text] [Related]
13. Among 17 inducers of differentiation only sodium butyrate causes a permanent down-regulation of c-myc in Burkitt's lymphoma. Rottleb C; Bornkamm GW; Polack A Int J Cancer; 1995 Sep; 62(6):697-702. PubMed ID: 7558417 [TBL] [Abstract][Full Text] [Related]
14. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Zimra Y; Wasserman L; Maron L; Shaklai M; Nudelman A; Rephaeli A J Cancer Res Clin Oncol; 1997; 123(3):152-60. PubMed ID: 9119880 [TBL] [Abstract][Full Text] [Related]
15. Derivatives of butyric acid as potential anti-neoplastic agents. Rephaeli A; Rabizadeh E; Aviram A; Shaklai M; Ruse M; Nudelman A Int J Cancer; 1991 Aug; 49(1):66-72. PubMed ID: 1874573 [TBL] [Abstract][Full Text] [Related]
16. Sodium butyrate suppresses the transforming activity of an activated N-ras oncogene in human colon carcinoma cells. Stoddart JH; Lane MA; Niles RM Exp Cell Res; 1989 Sep; 184(1):16-27. PubMed ID: 2676572 [TBL] [Abstract][Full Text] [Related]
17. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. Aviram A; Zimrah Y; Shaklai M; Nudelman A; Rephaeli A Int J Cancer; 1994 Mar; 56(6):906-9. PubMed ID: 8119779 [TBL] [Abstract][Full Text] [Related]
18. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Siu LL; Von Hoff DD; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Eckhardt SG Invest New Drugs; 1998; 16(2):113-9. PubMed ID: 9848574 [TBL] [Abstract][Full Text] [Related]
19. The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity. Gopas J; Ehrlich T; Cohen O; Wishniak O; Tainsky MA; Segal S; Rager-Zisman B; Isakov N Int J Cancer; 1992 Sep; 52(2):329-35. PubMed ID: 1521919 [TBL] [Abstract][Full Text] [Related]
20. Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Wang XM; Wang X; Li J; Evers BM Ann Surg; 1998 Jun; 227(6):922-31. PubMed ID: 9637556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]